Literature DB >> 22294205

Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling.

Salvatore J Coniglio1, Eliseo Eugenin, Kostantin Dobrenis, E Richard Stanley, Brian L West, Marc H Symons, Jeffrey E Segall.   

Abstract

Glioblastoma multiforme is a deadly cancer for which current treatment options are limited. The ability of glioblastoma tumor cells to infiltrate the surrounding brain parenchyma critically limits the effectiveness of current treatments. We investigated how microglia, the resident macrophages of the brain, stimulate glioblastoma cell invasion. We first examined the ability of normal microglia from C57Bl/6J mice to stimulate GL261 glioblastoma cell invasion in vitro. We found that microglia stimulate the invasion of GL261 glioblastoma cells by approximately eightfold in an in vitro invasion assay. Pharmacological inhibition of epidermal growth factor receptor (EGFR) strongly inhibited microglia-stimulated invasion. Furthermore, blockade of colony stimulating factor 1 receptor (CSF-1R) signaling using ribonucleic acid (RNA) interference or pharmacological inhibitors completely inhibited microglial enhancement of glioblastoma invasion. GL261 cells were found to constitutively secrete CSF-1, the levels of which were unaffected by epidermal growth factor (EGF) stimulation, EGFR inhibition or coculture with microglia. CSF-1 only stimulated microglia invasion, whereas EGF only stimulated glioblastoma cell migration, demonstrating a synergistic interaction between these two cell types. Finally, using PLX3397 (a CSF-1R inhibitor that can cross the blood-brain barrier) in live animals, we discovered that blockade of CSF-1R signaling in vivo reduced the number of tumor-associated microglia and glioblastoma invasion. These data indicate that glioblastoma and microglia interactions mediated by EGF and CSF-1 can enhance glioblastoma invasion and demonstrate the possibility of inhibiting glioblastoma invasion by targeting glioblastoma-associated microglia via inhibition of the CSF-1R.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22294205      PMCID: PMC3356419          DOI: 10.2119/molmed.2011.00217

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  24 in total

1.  Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation.

Authors:  Girish C Daginakatte; Scott M Gianino; Nina W Zhao; Alexander S Parsadanian; David H Gutmann
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

Review 2.  Trophic macrophages in development and disease.

Authors:  Jeffrey W Pollard
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

Review 3.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

Review 4.  Malignant astrocytic glioma: genetics, biology, and paths to treatment.

Authors:  Frank B Furnari; Tim Fenton; Robert M Bachoo; Akitake Mukasa; Jayne M Stommel; Alexander Stegh; William C Hahn; Keith L Ligon; David N Louis; Cameron Brennan; Lynda Chin; Ronald A DePinho; Webster K Cavenee
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

5.  CSF-1 receptor structure/function in MacCsf1r-/- macrophages: regulation of proliferation, differentiation, and morphology.

Authors:  Wenfeng Yu; Jian Chen; Ying Xiong; Fiona J Pixley; Xu-Ming Dai; Yee-Guide Yeung; E Richard Stanley
Journal:  J Leukoc Biol       Date:  2008-06-17       Impact factor: 4.962

Review 6.  Central nervous system tumors.

Authors:  Jan C Buckner; Paul D Brown; Brian P O'Neill; Frederic B Meyer; Cynthia J Wetmore; Joon H Uhm
Journal:  Mayo Clin Proc       Date:  2007-10       Impact factor: 7.616

7.  Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.

Authors:  A Wesolowska; A Kwiatkowska; L Slomnicki; M Dembinski; A Master; M Sliwa; K Franciszkiewicz; S Chouaib; B Kaminska
Journal:  Oncogene       Date:  2007-08-06       Impact factor: 9.867

8.  Discovery of novel FMS kinase inhibitors as anti-inflammatory agents.

Authors:  Carl R Illig; Jinsheng Chen; Mark J Wall; Kenneth J Wilson; Shelley K Ballentine; M Jonathan Rudolph; Renee L DesJarlais; Yanmin Chen; Carsten Schubert; Ioanna Petrounia; Carl S Crysler; Christopher J Molloy; Margery A Chaikin; Carl L Manthey; Mark R Player; Bruce E Tomczuk; Sanath K Meegalla
Journal:  Bioorg Med Chem Lett       Date:  2008-01-19       Impact factor: 2.823

9.  Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas.

Authors:  Y Komohara; K Ohnishi; J Kuratsu; M Takeya
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

Review 10.  The epidermal growth factor receptor ligands at a glance.

Authors:  Marlon R Schneider; Eckhard Wolf
Journal:  J Cell Physiol       Date:  2009-03       Impact factor: 6.384

View more
  169 in total

Review 1.  Central nervous system myeloid cells as drug targets: current status and translational challenges.

Authors:  Knut Biber; Thomas Möller; Erik Boddeke; Marco Prinz
Journal:  Nat Rev Drug Discov       Date:  2015-12-04       Impact factor: 84.694

2.  Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer.

Authors:  Souhil Lebdai; Mathieu Gigoux; Ricardo Alvim; Alexander Somma; Karan Nagar; Abdel Rahmene Azzouzi; Olivier Cussenot; Taha Merghoub; Jedd D Wolchok; Avigdor Scherz; Kwanghee Kim; Jonathan Coleman
Journal:  Oncoimmunology       Date:  2019-03-28       Impact factor: 8.110

Review 3.  Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.

Authors:  William Tomaszewski; Luis Sanchez-Perez; Thomas F Gajewski; John H Sampson
Journal:  Clin Cancer Res       Date:  2019-02-25       Impact factor: 12.531

Review 4.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

5.  Collective invasion of glioma cells through OCT1 signalling and interaction with reactive astrocytes after surgery.

Authors:  Yangjin Kim; Donggu Lee; Sean Lawler
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2020-07-27       Impact factor: 6.237

6.  CSF1 overexpression has pleiotropic effects on microglia in vivo.

Authors:  Ishani De; Maria Nikodemova; Megan D Steffen; Emily Sokn; Vilena I Maklakova; Jyoti J Watters; Lara S Collier
Journal:  Glia       Date:  2014-07-05       Impact factor: 7.452

7.  Microglia dictate the impact of saturated fat consumption on hypothalamic inflammation and neuronal function.

Authors:  Martin Valdearcos; Megan M Robblee; Daniel I Benjamin; Daniel K Nomura; Allison W Xu; Suneil K Koliwad
Journal:  Cell Rep       Date:  2014-12-11       Impact factor: 9.423

8.  Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.

Authors:  Rikke B Holmgaard; Alexandra Brachfeld; Billel Gasmi; David R Jones; Marissa Mattar; Thompson Doman; Mary Murphy; David Schaer; Jedd D Wolchok; Taha Merghoub
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

9.  The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.

Authors:  Daniela F Quail; Robert L Bowman; Leila Akkari; Marsha L Quick; Alberto J Schuhmacher; Jason T Huse; Eric C Holland; James C Sutton; Johanna A Joyce
Journal:  Science       Date:  2016-05-20       Impact factor: 47.728

10.  S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages.

Authors:  Huaqing Wang; Leying Zhang; Ian Y Zhang; Xuebo Chen; Anna Da Fonseca; Shihua Wu; Hui Ren; Sam Badie; Sam Sadeghi; Mao Ouyang; Charles D Warden; Behnam Badie
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.